Association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: A case report
Semaglutide is a glucagon-like peptide-1 receptor agonist used in the treatment of type 2 diabetes mellitus and management of obesity. Associations of glucagon-like peptide-1 receptor agonist use with psychiatric adverse events and suicidal behavior have been reported. A man in his late 70s with typ...
Saved in:
Main Authors: | Anisija Stojkovska, Polona Rus Prelog, Anja Kokalj Palandacic |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-07-01
|
Series: | Journal of International Medical Research |
Online Access: | https://doi.org/10.1177/03000605251349393 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Self-Reported Symptoms Related to Depression and Suicidal Risk
by: Yoshimasu, Kouichi, et al.
Published: (2012) -
Semaglutide ameliorates diabetes-associated cognitive dysfunction in mouse model of type 2 diabetes
by: Yan Zhu, et al.
Published: (2025-01-01) -
Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease
by: Takao Kato, et al.
Published: (2025-07-01) -
Suicidality and symptoms of anxiety, irritability, and agitation in patients experiencing manic episodes with depressive symptoms: a naturalistic study
by: Eberhard J, et al.
Published: (2016-08-01) -
Relation between suicide ideation and depression, anxious symptoms, rumination and self-acceptance in adolescents with depressive disorder
by: YU Xiaolei, et al.
Published: (2025-07-01)